https://m2.mtmt.hu/ hun 2026-09-23 01:38 JournalArticle 36104220 VALIDATED true Paál A and Dora D shared first authorship. Varga Zoltan V and Görbe A shared last authorship. A helyes szerzői sorrend: ... Varga Z, Lohinai, Z, Görbe A. A megosztott utolsó szerzőség jelölése miatt volt szükség a cserére. 0 false 2026-08-10T20:25:47.547+0000 2026-01-06T12:45:49.342+0000 2025-04-23T13:32:10.893+0000 true 10015206 Áncsán Gizella /api/admin/10015206 Admin Áncsán Gizella (SE admin) true 10015206 2026-07-19T11:03:35.842+0000 2025-06-19T11:38:05.088+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Tichy Rita (SE_KK_Admin5_TR, admin) true 10026589 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Paál, Ágnes true true /api/journal/10032813 REVIEWED CANCERS 2072-6694 true false 10032813 false 10032813 true 2072-6694 Journal FOREIGN 17 9 1407 1407 26 2025 Background/Objectives: Small cell lung cancer (SCLC) is one of the malignancies with the worst prognosis, and there have been no major breakthroughs in its treatment for a long time. The majority of patients are diagnosed at the extensive stage, where the only option is chemotherapy, and even the addition of immune checkpoint inhibitors results in only modest benefits. The characterization of the molecular mechanisms behind therapy resistance has relevance in finding novel therapeutic approaches. Previous studies showed the possibility of annexin A1’s (ANXA1) involvement in the immunosuppressive tumor microenvironment in SCLC, and there are studies showing the direct effects of ANXA1 modulation on cancer cell aggressiveness. Methods: We aimed to characterize the roles of ANXA1 expression using publicly available transcriptomic data, the RNA-seq-based predictive algorithms EPIC and ESTIMATE, and immunohistochemistry on patient samples. For the in vitro studies, we silenced ANXA1 expression with short hairpin RNA in three SCLC cell lines, measured the growth rate with the trypan blue exclusion assay, assessed the chemosensitivity to cisplatin and etoposide with the Presto BlueTM viability assay, and performed Western blots to assess changes in the levels of metabolic and mesenchymal markers and transcriptional drivers. Results: ANXA1-high tumors are associated with significantly increased immune infiltrates, stromality, and tumor-associated macrophages (TAMs). The ANXA1 protein is expressed on tumor cells and TAMs at the tissue level. ANXA1 silencing in H841 cells did not affect the growth rate; in SW1271 cells, shANXA1 cells grew significantly slower than shCTRL cells. Meanwhile, in H1048 cells, proliferation was significantly faster. Despite the different growth rates of the tested cell lines, ANXA1 silencing decreased the chemosensitivity to both cisplatin and etoposide in all three cell lines. Gene expression changes in mesenchymal markers, metabolic markers, dominant transcriptional drivers, and immune-relevant molecules were also characterized. Conclusions: This is the first comprehensive characterization of ANXA1 in SCLC to reveal its role in the tumor’s cell biology and the TME, aiming to boost further research in the field. Funding 2052282 /api/funding/2052282 (RRF-2.3.1-21-2022-00003) false true Funding 2052283 /api/funding/2052283 (2022-1.1.1-KK-2022-00005) false true Funding 2052284 /api/funding/2052284 (TKP2021-EGA-23) Támogató: Innovációs és Technológiai Minisztérium false true Funding 2052285 /api/funding/2052285 National Research, Development and Innovation Office (NKFIH) of Hungary(FK134751) false true Funding 2052286 /api/funding/2052286 (K139237) false true Funding 2052287 /api/funding/2052287 (FK146775) false true Funding 2052288 /api/funding/2052288 (PD142287) false true Funding 2052289 /api/funding/2052289 (LP-2021-38) Támogató: Hungarian Academy of Sciences false true Funding 2052290 /api/funding/2052290 (2019-1.1.1-PIACI-KFI-2019-00367) false true Funding 2052291 /api/funding/2052291 (ÚNKP-23-5) false true true 2025 true true true false true false GOLD 2026-08-10 true https://doi.org/10.3390/cancers17091407 2 0 2 2 0 2 2 2 2 2 2 2 2 2 0 0 2 2 2 2 0 8 8 Folyóiratcikk Journal Article 24 2 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2026 0 2 2 2 2 Q1 false false false false 2025-04-27T08:02:51.654+0000 Anatómiai, Szövet- és Fejlődéstani Intézet (SE / AOK / I); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI); MTA-SE Momentum Kardio-Onkológia és Kardioimmun... (SE / AOK / I / FFI); Transzlációs Medicina Intézet (SE / AOK / I) 7 33 6 12 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 126239818 /api/authorship/126239818 Paál, Ágnes [Paál, Ágnes (farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI); MTA-SE Momentum Kardio-Onkológia és Kardioimmun... (SE / AOK / I / FFI); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 1 0.083 true false false Author 10077413 /api/author/10077413 Paál Ágnes (farmakológia) Paál Ágnes true true Paál Ágnes true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126239819 /api/authorship/126239819 Dora, David* [Dóra, Dávid (Fejlődésbiológia), szerző] Anatómiai, Szövet- és Fejlődéstani Intézet (SE / AOK / I) 2 0.083 true false false Author 10050618 /api/author/10050618 Dóra Dávid (Fejlődésbiológia) Dóra Dávid true 10050618 true Dora David true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126239820 /api/authorship/126239820 Takács, Ákos [Takács, Ákos (patobiokémia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 3 0.083 false false false Author 10077661 /api/author/10077661 Takács Ákos (patobiokémia) Takács Ákos true true Takács Ákos true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126239821 /api/authorship/126239821 Rivard, Christopher 4 0.083333336 false false false Rivard Christopher true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126239822 /api/authorship/126239822 Pickard, Shivaun Lueke 5 0.083333336 false false false Pickard Shivaun Lueke true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126239823 /api/authorship/126239823 Hirsch, Fred R. 6 0.083333336 false false false Hirsch Fred R. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126239824 /api/authorship/126239824 Roskó, Brigitta 7 0.083333336 false false false Roskó Brigitta true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126239825 /api/authorship/126239825 Kiraly, Peter 8 0.083333336 false false false Kiraly Peter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126239826 /api/authorship/126239826 Ferdinandy, Péter [Ferdinandy, Péter (Farmakológia, mol...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 9 0.083 false false false Author 10010125 /api/author/10010125 Ferdinandy Péter (Farmakológia, molekuláris medicina) Ferdinandy Péter true 10010125 true Ferdinandy Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126239828 /api/authorship/126239828 Lohinai, Zoltan ✉ [Lohinai, Zoltán (Onkológia), szerző] Transzlációs Medicina Intézet (SE / AOK / I) 10 0.083 false false true Author 10044743 /api/author/10044743 Lohinai Zoltán (Onkológia) Lohinai Zoltán true 10044743 true Lohinai Zoltan true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126239827 /api/authorship/126239827 Varga, Zoltán V.** [Varga, Zoltán (kardiovaszkuláris...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI); MTA-SE Momentum Kardio-Onkológia és Kardioimmun... (SE / AOK / I / FFI) 11 0.083 false true false Author 10028393 /api/author/10028393 Varga Zoltán (kardiovaszkuláris kutatás) Varga Zoltán true 10028393 true Varga Zoltán V. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 126239829 /api/authorship/126239829 Görbe, Anikó ✉ [Görbe, Anikó (orvostudomany), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 12 0.083 false true true Author 10027602 /api/author/10027602 Görbe Anikó (orvostudomany) Görbe Anikó true 10027602 true Görbe Anikó true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 29269357 /api/publicationidentifier/29269357 DOI: 10.3390/cancers17091407 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.3390/cancers17091407 https://doi.org/10.3390/cancers17091407 false true PublicationIdentifier 29413610 /api/publicationidentifier/29413610 WoS: 001487449300001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001487449300001 https://www.webofscience.com/wos/woscc/full-record/001487449300001 true true PublicationIdentifier 29413619 /api/publicationidentifier/29413619 Scopus: 105005097638 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105005097638 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105005097638 true true PublicationIdentifier 29421414 /api/publicationidentifier/29421414 PubMed: 40361334 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 40361334 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40361334&dopt=Abstract true true PublicationIdentifier 31897745 /api/publicationidentifier/31897745 Egyéb URL: https://www.mdpi.com/2072-6694/17/9/1407 PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true IDENTICAL https://www.mdpi.com/2072-6694/17/9/1407 https://www.mdpi.com/2072-6694/17/9/1407 false true SjrRating 11609292 /api/sjrrating/11609292 sjr:Q1 (2025) Scopus - Oncology CANCERS 2072-6694 92 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2730 /api/classificationexternal/2730 Scopus - Oncology true 2730 true Q1 DIRECT true true Reference 65477900 /api/reference/65477900 1. George 2015: Comprehensive genomic profiles of small cell lung cancer., Nature, 524, p. 47, DOI: 10.1038/nature14664 1 10.1038/nature14664 false true Reference 65477901 /api/reference/65477901 2. Araghi 2023: Recent advances in non-small cell lung cancer targeted therapy; an update review., Cancer Cell Int., 23, p. 162, DOI: 10.1186/s12935-023-02990-y 2 10.1186/s12935-023-02990-y false true Reference 65477902 /api/reference/65477902 3. Yu 2021: Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer., J. Drug Target., 29, p. 1, DOI: 10.1080/1061186X.2020.1797050 3 10.1080/1061186X.2020.1797050 false true Reference 65477903 /api/reference/65477903 4. Liu 2023: Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide., Lung Cancer, 186, p. 107418, DOI: 10.1016/j.lungcan.2023.107418 4 10.1016/j.lungcan.2023.107418 false true Reference 65477904 /api/reference/65477904 5. Chen 2022: Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN., ESMO Open, 7, p. 100408, DOI: 10.1016/j.esmoop.2022.100408 5 10.1016/j.esmoop.2022.100408 false true Reference 65477905 /api/reference/65477905 6. Ganti 2021: Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology., J. Natl. Compr. Cancer Netw., 19, p. 1441, DOI: 10.6004/jnccn.2021.0058 6 10.6004/jnccn.2021.0058 false true Reference 65477906 /api/reference/65477906 7. Remon 2021: Small cell lung cancer: A slightly less orphan disease after immunotherapy., Ann. Oncol., 32, p. 698, DOI: 10.1016/j.annonc.2021.02.025 7 10.1016/j.annonc.2021.02.025 false true Reference 65477907 /api/reference/65477907 8. Fur 2024: Applied models and molecular characteristics of small cell lung cancer., Pathol. Oncol. Res., 30, p. 1611743, DOI: 10.3389/pore.2024.1611743 8 10.3389/pore.2024.1611743 false true Reference 65477908 /api/reference/65477908 9. Rudin 2019: Molecular subtypes of small cell lung cancer: A synthesis of human and mouse model data., Nat. Rev. Cancer, 19, p. 289, DOI: 10.1038/s41568-019-0133-9 9 10.1038/s41568-019-0133-9 false true Reference 65477909 /api/reference/65477909 10. Desai 2024: Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities., Cell Rep. Med., 5, p. 101610, DOI: 10.1016/j.xcrm.2024.101610 10 10.1016/j.xcrm.2024.101610 false true Reference 65477910 /api/reference/65477910 11. Ireland 2020: MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate., Cancer Cell, 38, p. 60, DOI: 10.1016/j.ccell.2020.05.001 11 10.1016/j.ccell.2020.05.001 false true Reference 65477911 /api/reference/65477911 12. Dora 2020: Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution., Mol. Oncol., 14, p. 1947, DOI: 10.1002/1878-0261.12741 12 10.1002/1878-0261.12741 false true Reference 65477912 /api/reference/65477912 13. Dora, D., Rivard, C., Yu, H., Pickard, S.L., Laszlo, V., Harko, T., Megyesfalvi, Z., Dinya, E., Gerdan, C., and Szegvari, G. (2021). Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer. Biology, 10., DOI: 10.3390/biology10060502 13 10.3390/biology10060502 false true Reference 65477913 /api/reference/65477913 14. Kelly 2022: Annexin-A1: The culprit or the solution?., Immunology, 166, p. 2, DOI: 10.1111/imm.13455 14 10.1111/imm.13455 false true Reference 65477914 /api/reference/65477914 15. Wei 2021: Knockdown of Annexin-A1 Inhibits Growth, Migration and Invasion of Glioma Cells by Suppressing the PI3K/Akt Signaling Pathway., ASN Neuro, 13, p. 17590914211001218, DOI: 10.1177/17590914211001218 15 10.1177/17590914211001218 false true Reference 65477915 /api/reference/65477915 16. Elakad 2021: Role of Annexin A1 in Squamous Cell Lung Cancer Progression., Dis. Markers, 2021, p. 5520832, DOI: 10.1155/2021/5520832 16 10.1155/2021/5520832 false true Reference 65477916 /api/reference/65477916 17. Crichton 2024: A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo., Oncogene, 43, p. 608, DOI: 10.1038/s41388-023-02919-9 17 10.1038/s41388-023-02919-9 false true Reference 65477917 /api/reference/65477917 18. Chen 2021: Annexin A1 is a potential biomarker of bone metastasis in small cell lung cancer., Oncol. Lett., 21, p. 141, DOI: 10.3892/ol.2020.12402 18 10.3892/ol.2020.12402 false true Reference 65477918 /api/reference/65477918 19. Liu 2015: Brain microvascular endothelium induced-annexin A1 secretion contributes to small cell lung cancer brain metastasis., Int. J. Biochem. Cell Biol., 66, p. 11, DOI: 10.1016/j.biocel.2015.06.019 19 10.1016/j.biocel.2015.06.019 false true Reference 65477919 /api/reference/65477919 20. Cerami 2012: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data., Cancer Discov., 2, p. 401, DOI: 10.1158/2159-8290.CD-12-0095 20 10.1158/2159-8290.CD-12-0095 false true Reference 65477920 /api/reference/65477920 21. Yoshihara 2013: Inferring tumour purity and stromal and immune cell admixture from expression data., Nat. Commun., 4, p. 2612, DOI: 10.1038/ncomms3612 21 10.1038/ncomms3612 false true Reference 65477921 /api/reference/65477921 22. Racle 2020: EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data., Methods Mol. Biol., 2120, p. 233, DOI: 10.1007/978-1-0716-0327-7_17 22 10.1007/978-1-0716-0327-7_17 false true Reference 65477922 /api/reference/65477922 23. Morales 2022: A joint NCBI and EMBL-EBI transcript set for clinical genomics and research., Nature, 604, p. 310, DOI: 10.1038/s41586-022-04558-8 23 10.1038/s41586-022-04558-8 false true Reference 65477923 /api/reference/65477923 24. Voros, I., Onodi, Z., Toth, V.E., Gergely, T.G., Saghy, E., Gorbe, A., Kemeny, A., Leszek, P., Helyes, Z., and Ferdinandy, P. (2022). Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone. Biomedicines, 10., DOI: 10.3390/biomedicines10071573 24 10.3390/biomedicines10071573 false true Reference 65477924 /api/reference/65477924 25. Moraes, L.A., Kar, S., Foo, S.L., Gu, T., Toh, Y.Q., Ampomah, P.B., Sachaphibulkij, K., Yap, G., Zharkova, O., and Lukman, H.M. (2017). Annexin-A1 enhances breast cancer growth and migration by promoting alternative macrophage polarization in the tumour microenvironment. Sci. Rep., 7., DOI: 10.1038/s41598-017-17622-5 25 10.1038/s41598-017-17622-5 false true Reference 65477925 /api/reference/65477925 26. Vaupel 2021: Revisiting the Warburg effect: Historical dogma versus current understanding., J. Physiol., 599, p. 1745, DOI: 10.1113/JP278810 26 10.1113/JP278810 false true Reference 65477926 /api/reference/65477926 27. Foo 2019: Annexin-A1—A Blessing or a Curse in Cancer?., Trends Mol. Med., 25, p. 315, DOI: 10.1016/j.molmed.2019.02.004 27 10.1016/j.molmed.2019.02.004 false true Reference 65477927 /api/reference/65477927 28. Schmidt 2010: Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells., Proc. Natl. Acad. Sci. USA, 107, p. 6340, DOI: 10.1073/pnas.0913360107 28 10.1073/pnas.0913360107 false true Reference 65477928 /api/reference/65477928 29. Moraes 2018: Annexin A1 in inflammation and breast cancer: A new axis in the tumor microenvironment., Cell Adh Migr., 12, p. 417 29 false true Reference 65477929 /api/reference/65477929 30. Xiao 2023: ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers., Cancer Immunol. Res., 11, p. 1367, DOI: 10.1158/2326-6066.CIR-22-0896 30 10.1158/2326-6066.CIR-22-0896 false true Reference 65477930 /api/reference/65477930 31. Valkenburg 2018: Targeting the tumour stroma to improve cancer therapy., Nat. Rev. Clin. Oncol., 15, p. 366, DOI: 10.1038/s41571-018-0007-1 31 10.1038/s41571-018-0007-1 false true Reference 65477931 /api/reference/65477931 32. Liu 2013: Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophages., Cancer Res., 73, p. 550, DOI: 10.1158/0008-5472.CAN-12-2290 32 10.1158/0008-5472.CAN-12-2290 false true Reference 65477932 /api/reference/65477932 33. Bist 2013: Annexin-A1 regulates TLR-mediated IFN-beta production through an interaction with TANK-binding kinase 1., J. Immunol., 191, p. 4375, DOI: 10.4049/jimmunol.1301504 33 10.4049/jimmunol.1301504 false true Reference 65477933 /api/reference/65477933 34. Wu 2022: Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma., Cancer Discov., 12, p. 2820, DOI: 10.1158/2159-8290.CD-22-0196 34 10.1158/2159-8290.CD-22-0196 false true Reference 65477934 /api/reference/65477934 35. Bai 2020: Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer., J. Immunother. Cancer, 8, p. e000169, DOI: 10.1136/jitc-2019-000169 35 10.1136/jitc-2019-000169 false true Reference 65477935 /api/reference/65477935 36. Radomir 2021: The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5., Nat. Commun., 12, p. 1893, DOI: 10.1038/s41467-021-22230-z 36 10.1038/s41467-021-22230-z false true Reference 65477936 /api/reference/65477936 37. Yang 2023: Cancer-associated fibroblasts: From basic science to anticancer therapy., Exp. Mol. Med., 55, p. 1322, DOI: 10.1038/s12276-023-01013-0 37 10.1038/s12276-023-01013-0 false true Reference 65477937 /api/reference/65477937 38. Brown 2009: Nox proteins in signal transduction., Free Radic. Biol. Med., 47, p. 1239, DOI: 10.1016/j.freeradbiomed.2009.07.023 38 10.1016/j.freeradbiomed.2009.07.023 false true Reference 65477938 /api/reference/65477938 39. Bedard 2007: The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology., Physiol. Rev., 87, p. 245, DOI: 10.1152/physrev.00044.2005 39 10.1152/physrev.00044.2005 false true Reference 65477939 /api/reference/65477939 40. Shah 2021: T cell receptor (TCR) signaling in health and disease., Signal Transduct. Target. Ther., 6, p. 412, DOI: 10.1038/s41392-021-00823-w 40 10.1038/s41392-021-00823-w false true Reference 65477940 /api/reference/65477940 41. Waldmann, T.A. (2018). Cytokines in Cancer Immunotherapy. Cold Spring Harb. Perspect. Biol., 10., DOI: 10.1101/cshperspect.a028472 41 10.1101/cshperspect.a028472 false true Reference 65477941 /api/reference/65477941 42. Bruni 2020: The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy., Nat. Rev. Cancer, 20, p. 662, DOI: 10.1038/s41568-020-0285-7 42 10.1038/s41568-020-0285-7 false true Reference 65477942 /api/reference/65477942 43. Zhang, D., Wang, W., Zhou, H., Su, L., Han, X., Zhang, X., Han, W., Wang, Y., and Xue, X. (2022). ANXA1: An Important Independent Prognostic Factor and Molecular Target in Glioma. Front. Genet., 13., DOI: 10.3389/fgene.2022.851505 43 10.3389/fgene.2022.851505 false true Reference 65477943 /api/reference/65477943 44. Liu 2011: Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma., Clin. Exp. Metastasis, 28, p. 413, DOI: 10.1007/s10585-011-9380-1 44 10.1007/s10585-011-9380-1 false true Reference 65477944 /api/reference/65477944 45. Bai 2004: Overexpression of annexin 1 in pancreatic cancer and its clinical significance., World J. Gastroenterol., 10, p. 1466, DOI: 10.3748/wjg.v10.i10.1466 45 10.3748/wjg.v10.i10.1466 false true Reference 65477945 /api/reference/65477945 46. Cheng 2012: Annexin A1 is associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway., Cancer, 118, p. 5757, DOI: 10.1002/cncr.27565 46 10.1002/cncr.27565 false true Reference 65477946 /api/reference/65477946 47. Manai 2020: Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer., In Vivo, 34, p. 177, DOI: 10.21873/invivo.11759 47 10.21873/invivo.11759 false true Reference 65477947 /api/reference/65477947 48. Fang 2016: Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro., Mol. Med. Rep., 13, p. 3858, DOI: 10.3892/mmr.2016.5022 48 10.3892/mmr.2016.5022 false true Reference 65477948 /api/reference/65477948 49. Zhu 2022: Potential regulatory mechanism of TNF-alpha/TNFR1/ANXA1 in glioma cells and its role in glioma cell proliferation., Open Life Sci., 17, p. 208, DOI: 10.1515/biol-2022-0023 49 10.1515/biol-2022-0023 false true Reference 65477949 /api/reference/65477949 50. Zhao 2021: ANXA1 enhances tumor proliferation and migration by regulating epithelial-mesenchymal transition and IL-6/JAK2/STAT3 pathway in papillary thyroid carcinoma., J. Cancer, 12, p. 1295, DOI: 10.7150/jca.52171 50 10.7150/jca.52171 false true Reference 65477950 /api/reference/65477950 51. Wan 2017: ANXA1 affects cell proliferation, invasion and epithelial-mesenchymal transition of oral squamous cell carcinoma., Exp. Ther. Med., 14, p. 5214 51 false true Reference 65477951 /api/reference/65477951 52. Deng 2021: ANXA1-GSK3beta interaction and its involvement in NSCLC metastasis., Acta Biochim. Biophys. Sin., 53, p. 912, DOI: 10.1093/abbs/gmab067 52 10.1093/abbs/gmab067 false true Reference 65477952 /api/reference/65477952 53. Gao 2024: An overview of the regulatory role of annexin A1 in the tumor microenvironment and its prospective clinical application (Review)., Int. J. Oncol., 64, p. 51, DOI: 10.3892/ijo.2024.5639 53 10.3892/ijo.2024.5639 false true Reference 65477953 /api/reference/65477953 54. Gbelcova 2014: The complex understanding of Annexin A1 phosphorylation., Cell Signal, 26, p. 173, DOI: 10.1016/j.cellsig.2013.09.020 54 10.1016/j.cellsig.2013.09.020 false true Reference 65477954 /api/reference/65477954 55. Charlier 2004: Fatal overdosage with cisplatin., J. Anal. Toxicol., 28, p. 138, DOI: 10.1093/jat/28.2.138 55 10.1093/jat/28.2.138 false true Reference 65477955 /api/reference/65477955 56. Ando 1996: Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer., Jpn. J. Cancer Res., 87, p. 200, DOI: 10.1111/j.1349-7006.1996.tb03159.x 56 10.1111/j.1349-7006.1996.tb03159.x false true Reference 65477956 /api/reference/65477956 57. Liston 2017: Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies., Clin. Cancer Res., 23, p. 3489, DOI: 10.1158/1078-0432.CCR-16-3083 57 10.1158/1078-0432.CCR-16-3083 false true Reference 65477957 /api/reference/65477957 58. Schulz 2012: Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics., Crit. Care, 16, p. R136, DOI: 10.1186/cc11441 58 10.1186/cc11441 false true Reference 65477958 /api/reference/65477958 59. Tang, L., Chen, Y., Chen, H., Jiang, P., Yan, L., Mo, D., Tang, X., and Yan, F. (2020). DCST1-AS1 Promotes TGF-beta-Induced Epithelial-Mesenchymal Transition and Enhances Chemoresistance in Triple-Negative Breast Cancer Cells via ANXA1. Front. Oncol., 10., DOI: 10.3389/fonc.2020.00280 59 10.3389/fonc.2020.00280 false true Reference 65477959 /api/reference/65477959 60. Ren 2023: Annexin A1 induces oxaliplatin resistance of gastric cancer through autophagy by targeting PI3K/AKT/mTOR., FASEB J., 37, p. e22790, DOI: 10.1096/fj.202200400RR 60 10.1096/fj.202200400RR false true Reference 65477960 /api/reference/65477960 61. Wang 2014: Regulatory mechanisms of annexin-induced chemotherapy resistance in cisplatin resistant lung adenocarcinoma., Asian Pac. J. Cancer Prev., 15, p. 3191, DOI: 10.7314/APJCP.2014.15.7.3191 61 10.7314/APJCP.2014.15.7.3191 false true Reference 65477961 /api/reference/65477961 62. Yu 2014: Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer., Int. J. Clin. Exp. Pathol., 7, p. 5538 62 false true Reference 65477962 /api/reference/65477962 63. Sato 2011: Up-regulated Annexin A1 expression in gastrointestinal cancer is associated with cancer invasion and lymph node metastasis., Exp. Ther. Med., 2, p. 239, DOI: 10.3892/etm.2011.210 63 10.3892/etm.2011.210 false true Reference 65477963 /api/reference/65477963 64. Gibbs 2018: Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer., Oncotarget, 9, p. 2697, DOI: 10.18632/oncotarget.23627 64 10.18632/oncotarget.23627 false true Reference 65477964 /api/reference/65477964 65. Maschler 2010: Annexin A1 attenuates EMT and metastatic potential in breast cancer., EMBO Mol. Med., 2, p. 401, DOI: 10.1002/emmm.201000095 65 10.1002/emmm.201000095 false true Reference 65477965 /api/reference/65477965 66. Hermes 2010: Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer—A retrospective single institution analysis., Respir. Med., 104, p. 1937, DOI: 10.1016/j.rmed.2010.07.013 66 10.1016/j.rmed.2010.07.013 false true Reference 65477966 /api/reference/65477966 67. Huang, L., Wang, C., Xu, H., and Peng, G. (2020). Targeting citrate as a novel therapeutic strategy in cancer treatment. Biochim. Biophys. Acta Rev. Cancer, 1873., DOI: 10.1016/j.bbcan.2019.188332 67 10.1016/j.bbcan.2019.188332 false true Reference 65477967 /api/reference/65477967 68. Liberti, M.V., and Locasale, J.W. (2016). Correction to: ‘The Warburg Effect: How Does it Benefit Cancer Cells?’: [Trends in Biochemical Sciences, 41 (2016) 211]. Trends Biochem. Sci., 41., DOI: 10.1016/j.tibs.2016.01.004 68 10.1016/j.tibs.2016.01.004 false true Reference 65477968 /api/reference/65477968 69. Jin 2016: Glutaminolysis as a target for cancer therapy., Oncogene, 35, p. 3619, DOI: 10.1038/onc.2015.447 69 10.1038/onc.2015.447 false true Reference 65477969 /api/reference/65477969 70. Saito 2022: The role of YAP1 in small cell lung cancer., Hum. Cell, 35, p. 628, DOI: 10.1007/s13577-022-00669-6 70 10.1007/s13577-022-00669-6 false true Reference 65477970 /api/reference/65477970 71. McColl 2017: Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer., Oncotarget, 8, p. 73745, DOI: 10.18632/oncotarget.20572 71 10.18632/oncotarget.20572 false true Reference 65477971 /api/reference/65477971 72. Pavan 2019: Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges., J. Immunother. Cancer, 7, p. 205, DOI: 10.1186/s40425-019-0690-1 72 10.1186/s40425-019-0690-1 false true Reference 65477972 /api/reference/65477972 73. Romero 2020: Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells., Cancer Immunol. Immunother., 69, p. 43, DOI: 10.1007/s00262-019-02437-2 73 10.1007/s00262-019-02437-2 false true Reference 65477973 /api/reference/65477973 74. Schulz 2024: Subcellular localization of PD-L1 and cell-cycle-dependent expression of nuclear PD-L1 variants: Implications for head and neck cancer cell functions and therapeutic efficacy., Mol. Oncol., 18, p. 431, DOI: 10.1002/1878-0261.13567 74 10.1002/1878-0261.13567 false true Reference 65477974 /api/reference/65477974 75. Yang, H., Xun, Y., and You, H. (2023). The landscape overview of CD47-based immunotherapy for hematological malignancies. Biomark. Res., 11., DOI: 10.1186/s40364-023-00456-x 75 10.1186/s40364-023-00456-x false true Reference 65477975 /api/reference/65477975 76. Tosi 2024: Extensive-stage small-cell lung cancer in patients receiving atezolizumab plus carboplatin-etoposide: Stratification of outcome based on a composite score that combines gene expression profiling and immune characterization of microenvironment., J. Immunother. Cancer, 12, p. e008974, DOI: 10.1136/jitc-2024-008974 76 10.1136/jitc-2024-008974 false true Reference 65477976 /api/reference/65477976 77. Martucci, N., Morabito, A., La Rocca, A., De Luca, G., De Cecio, R., Botti, G., Totaro, G., Muto, P., Picone, C., and Esposito, G. (2021). Surgery in Small-Cell Lung Cancer. Cancers, 13., DOI: 10.3390/cancers13030390 77 10.3390/cancers13030390 false true Reference 65477977 /api/reference/65477977 78. Goel, K., and Ploski, J.E. (2022). RISC-y Business: Limitations of Short Hairpin RNA-Mediated Gene Silencing in the Brain and a Discussion of CRISPR/Cas-Based Alternatives. Front. Mol. Neurosci., 15., DOI: 10.3389/fnmol.2022.914430 78 10.3389/fnmol.2022.914430 false true Reference 65477978 /api/reference/65477978 79. Burnett 2012: RNA-based therapeutics: Current progress and future prospects., Chem. Biol., 19, p. 60, DOI: 10.1016/j.chembiol.2011.12.008 79 10.1016/j.chembiol.2011.12.008 false true Reference 65477979 /api/reference/65477979 80. Ma 2007: An inducible system for expression and validation of the specificity of short hairpin RNA in mammalian cells., Nucleic Acids Res., 35, p. e22, DOI: 10.1093/nar/gkl1109 80 10.1093/nar/gkl1109 false true Reference 65477980 /api/reference/65477980 81. Moore 2010: Short hairpin RNA (shRNA): Design, delivery, and assessment of gene knockdown., Methods Mol. Biol., 629, p. 141 81 false true /api/publication/36104220 Paál Ágnes et al. Roles of Annexin A1 Expression in Small Cell Lung Cancer. (2025) CANCERS 2072-6694 17 9<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10077413"><a href="/gui2/?type=authors&mode=browse&sel=10077413" target="_blank">Paál Ágnes (<span class="authorship-author-name">Paál Ágnes</span> <span class="authorAux-mtmt"> farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/MTA-SE Momentum Kardio-Onkológia és Kardioimmunológia Kutatócsoport; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10050618"><a href="/gui2/?type=authors&mode=browse&sel=10050618" target="_blank">Dora David^* (<span class="authorship-author-name">Dóra Dávid</span> <span class="authorAux-mtmt"> Fejlődésbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Anatómiai, Szövet- és Fejlődéstani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10077661"><a href="/gui2/?type=authors&mode=browse&sel=10077661" target="_blank">Takács Ákos (<span class="authorship-author-name">Takács Ákos</span> <span class="authorAux-mtmt"> patobiokémia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Rivard Christopher </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Pickard Shivaun Lueke </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Hirsch Fred R. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Roskó Brigitta </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Kiraly Peter </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10010125"><a href="/gui2/?type=authors&mode=browse&sel=10010125" target="_blank">Ferdinandy Péter (<span class="authorship-author-name">Ferdinandy Péter</span> <span class="authorAux-mtmt"> Farmakológia, molekuláris medicina</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10044743"><a href="/gui2/?type=authors&mode=browse&sel=10044743" target="_blank">Lohinai Zoltan ✉ (<span class="authorship-author-name">Lohinai Zoltán</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10028393"><a href="/gui2/?type=authors&mode=browse&sel=10028393" target="_blank">Varga Zoltán V.^** (<span class="authorship-author-name">Varga Zoltán</span> <span class="authorAux-mtmt"> kardiovaszkuláris kutatás</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Farmakológiai és Farmakoterápiás Intézet">FFI</span>/MTA-SE Momentum Kardio-Onkológia és Kardioimmunológia Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10027602"><a href="/gui2/?type=authors&mode=browse&sel=10027602" target="_blank">Görbe Anikó ✉ (<span class="authorship-author-name">Görbe Anikó</span> <span class="authorAux-mtmt"> orvostudomany</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;36104220" target="_blank">Roles of Annexin A1 Expression in Small Cell Lung Cancer</a></div> <div> <span class="journal-title">CANCERS</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2072-6694">2072-6694</a>)</span>: <span class="journal-volume">17</span> <span class="journal-issue">9</span> <span class="page"> Paper 1407. 26 p. </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.3390/cancers17091407" target="_blank" href="https://doi.org/10.3390/cancers17091407"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001487449300001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001487449300001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105005097638" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105005097638"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="40361334" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40361334&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="https://www.mdpi.com/2072-6694/17/9/1407" target="_blank" href="https://www.mdpi.com/2072-6694/17/9/1407"> Egyéb URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Oncology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cancer Research&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 2</span> | Független: 2 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 2 | Scopus jelölt:&nbsp;2 | WoS/Scopus jelölt:&nbsp;2 | DOI jelölt:&nbsp;2 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;36104220&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 8 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 36104220</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (RRF-2.3.1-21-2022-00003), (2022-1.1.1-KK-2022-00005), (TKP2021-EGA-23) Támogató: Innovációs és Technológiai Minisztérium, National Research, Development and Innovation Office (NKFIH) of Hungary(FK134751), (K139237), (FK146775), (PD142287), (LP-2021-38) Támogató: Hungarian Academy of Sciences, (2019-1.1.1-PIACI-KFI-2019-00367), (ÚNKP-23-5) </div> <div class="lastModified">Utolsó módosítás: 2026.01.06. 13:45 Molnár-Taga Márta (SE 4-es admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Paál A and Dora D shared first authorship. Varga Zoltan V and Görbe A shared last authorship. A helyes szerzői sorrend: ... Varga Z, Lohinai, Z, Görbe A. A megosztott utolsó szerzőség jelölése miatt volt szükség a cserére.</pre> </div></div>